Table of Content


1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18

2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 32
2.2 Major Growth Drivers 36
2.3 Market Restraints and Challenges 44
2.4 Emerging Opportunities and Market Trends 47
2.5 Porter’s Fiver Forces Analysis 51

3 Segmentation of North America Market by Molecule 55
3.1 Market Overview by Molecule 55
3.2 Small Molecule APIs 57
3.3 Large Molecule APIs 58

4 Segmentation of North America Market by Synthesis 59
4.1 Market Overview by Synthesis 59
4.2 Synthetic API 61
4.2.1 Branded Synthetic API 62
4.2.2 Generic Synthetic API 63
4.3 Biotech API 64
4.3.1 Biotech API by Drug Type 65
4.3.1.1 Monoclonal Antibodies 66
4.3.1.2 Recombinant Proteins 67
4.3.1.3 Vaccines 68
4.3.1.4 Other Biotech APIs 69
4.3.2 Biotech API by Category 70
4.3.2.1 Innovative Biologic API 71
4.3.2.2 Generic Biosimilar API 72
4.3.3 Biotech API by Expression Technology 73
4.3.3.1 Mammalian Expression 74
4.3.3.2 Microbial Expression 75
4.3.3.3 Yeast Expression 76
4.3.3.4 Insect Expression 77
4.3.3.5 Other Expression Technologies 78
4.4 HPAPI 79
4.4.1 Branded HPAPI 80
4.4.2 Generic HPAPI 81

5 Segmentation of North America Market by Manufacturing Process 82
5.1 Market Overview by Manufacturing Process 82
5.2 Captive Manufacturing 84
5.2.1 Branded Captive API 85
5.2.2 Generic Captive API 86
5.3 Merchant Manufacturing 87
5.3.1 Merchant Manufacturing by Drug Type 88
5.3.1.1 Branded Merchant API 89
5.3.1.2 Generic Merchant API 90
5.3.2 Merchant Manufacturing by Drug Synthesis 91
5.3.2.1 Merchant Synthetic API 92
5.3.2.2 Merchant Biotech API 93

6 Segmentation of North America Market by Therapeutic Application 94
6.1 Market Overview by Therapeutic Application 94
6.2 Infectious Diseases 96
6.3 Oncology 97
6.4 Ophthalmology 98
6.5 Cardiovascular Disorders 99
6.6 Central Nervous System 100
6.7 Pulmonary Disorders 101
6.8 Orthopedics 102
6.9 Other Applications 103

7 Segmentation of North America Market by Drug Type 104
7.1 Market Overview by Drug Type 104
7.2 Branded Prescription Drugs 106
7.3 Generic Prescription Drugs 107
7.4 OTC Drugs 108

8 North America Market 2022-2032 by Country 109
8.1 Overview of North America Market 109
8.2 U.S. 112
8.3 Canada 122
8.4 Mexico 124

9 Competitive Landscape 126
9.1 Overview of Key Vendors 126
9.2 New Product Launch, Partnership, Investment, and M&A 129
9.3 Company Profiles 130
AbbVie Inc. 130
Astrazeneca 132
Aurobindo Pharma Ltd. 137
BASF 140
Bayer AG 143
Boehringer Ingelheim 147
Catalent Inc. 152
Dr. Reddy’s Laboratories 155
F. Hoffmann-La Roche 157
GlaxoSmithKline plc 160
Lonza Group 165
Lupin Limited 169
Merck & Co., Inc. 172
Mylan NV 175
Novartis International AG 178
Pfizer Inc. 181
Sanofi 186
Sun Pharmaceutical Industries Ltd. 189
Teva Pharmaceutical Industries Ltd. 192
Thermo Fisher Scientific 194
Related Reports and Products 197



List of Figures


List of Figures:

Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032 18
Figure 4. North America Active Pharmaceutical Ingredients (API) Market, 2022-2032, $ bn 21
Figure 5. Impact of COVID-19 on Business 25
Figure 6. Primary Drivers and Impact Factors of North America Active Pharmaceutical Ingredients (API) Market 36
Figure 7. GDP per capita in the World, 1960-2022, $ thousand 39
Figure 8. Leading Causes of Death in the World, 2000 and 2019, million 40
Figure 9. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 41
Figure 10. World Population 65 and Over, % of Total Population, 1950-2060 41
Figure 11. Primary Restraints and Impact Factors of North America Active Pharmaceutical Ingredients (API) Market 44
Figure 12. Investment Opportunity Analysis 48
Figure 13. Porter’s Fiver Forces Analysis of North America Active Pharmaceutical Ingredients (API) Market 51
Figure 14. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Molecule, 2022-2032, % of Revenue 56
Figure 15. North America Addressable Market Cap in 2023-2032 by Molecule, Value ($ bn) and Share (%) 56
Figure 16. North America Active Pharmaceutical Ingredients (API) Market by Molecule: Small Molecule APIs, 2022-2032, $ bn 57
Figure 17. North America Active Pharmaceutical Ingredients (API) Market by Molecule: Large Molecule APIs, 2022-2032, $ bn 58
Figure 18. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, % of Revenue 59
Figure 19. Contribution to North America 2023-2032 Cumulative Revenue by Synthesis, Value ($ bn) and Share (%) 60
Figure 20. North America Active Pharmaceutical Ingredients (API) Market by Synthesis: Synthetic API, 2022-2032, $ bn 61
Figure 21. North America Active Pharmaceutical Ingredients (API) Market by Synthetic API: Branded Synthetic API, 2022-2032, $ bn 62
Figure 22. North America Active Pharmaceutical Ingredients (API) Market by Synthetic API: Generic Synthetic API, 2022-2032, $ bn 63
Figure 23. North America Active Pharmaceutical Ingredients (API) Market by Synthesis: Biotech API, 2022-2032, $ bn 64
Figure 24. North America Biotech API Market by Drug Type: Monoclonal Antibodies, 2022-2032, $ bn 66
Figure 25. North America Biotech API Market by Drug Type: Recombinant Proteins, 2022-2032, $ bn 67
Figure 26. North America Biotech API Market by Drug Type: Vaccines, 2022-2032, $ bn 68
Figure 27. North America Biotech API Market by Drug Type: Other Biotech APIs, 2022-2032, $ bn 69
Figure 28. North America Biotech API Market by Category: Innovative Biologic API, 2022-2032, $ bn 71
Figure 29. North America Biotech API Market by Category: Generic Biosimilar API, 2022-2032, $ bn 72
Figure 30. North America Biotech API Market by Expression Technology: Mammalian Expression, 2022-2032, $ bn 74
Figure 31. North America Biotech API Market by Expression Technology: Microbial Expression, 2022-2032, $ bn 75
Figure 32. North America Biotech API Market by Expression Technology: Yeast Expression, 2022-2032, $ bn 76
Figure 33. North America Biotech API Market by Expression Technology: Insect Expression, 2022-2032, $ bn 77
Figure 34. North America Biotech API Market by Expression Technology: Other Expression Technologies, 2022-2032, $ bn 78
Figure 35. North America Active Pharmaceutical Ingredients (API) Market by Synthesis: HPAPI, 2022-2032, $ bn 79
Figure 36. North America Active Pharmaceutical Ingredients (API) Market by HPAPI: Branded HPAPI, 2022-2032, $ bn 80
Figure 37. North America Active Pharmaceutical Ingredients (API) Market by HPAPI: Generic HPAPI, 2022-2032, $ bn 81
Figure 38. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, % of Revenue 82
Figure 39. Contribution to North America 2023-2032 Cumulative Revenue by Manufacturing Process, Value ($ bn) and Share (%) 83
Figure 40. North America Active Pharmaceutical Ingredients (API) Market by Manufacturing Process: Captive Manufacturing, 2022-2032, $ bn 84
Figure 41. North America Active Pharmaceutical Ingredients (API) Market by Captive Manufacturing: Branded Captive API, 2022-2032, $ bn 85
Figure 42. North America Active Pharmaceutical Ingredients (API) Market by Captive Manufacturing: Generic Captive API, 2022-2032, $ bn 86
Figure 43. North America Active Pharmaceutical Ingredients (API) Market by Manufacturing Process: Merchant Manufacturing, 2022-2032, $ bn 87
Figure 44. North America API Merchant Manufacturing Market by Drug Type: Branded Merchant API, 2022-2032, $ bn 89
Figure 45. North America API Merchant Manufacturing Market by Drug Type: Generic Merchant API, 2022-2032, $ bn 90
Figure 46. North America API Merchant Manufacturing Market by Drug Synthesis: Merchant Synthetic API, 2022-2032, $ bn 92
Figure 47. North America API Merchant Manufacturing Market by Drug Synthesis: Merchant Biotech API, 2022-2032, $ bn 93
Figure 48. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, % of Revenue 94
Figure 49. Contribution to North America 2023-2032 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%) 95
Figure 50. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Infectious Diseases, 2022-2032, $ bn 96
Figure 51. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Oncology, 2022-2032, $ bn 97
Figure 52. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Ophthalmology, 2022-2032, $ bn 98
Figure 53. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Cardiovascular Disorders, 2022-2032, $ bn 99
Figure 54. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Central Nervous System, 2022-2032, $ bn 100
Figure 55. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Pulmonary Disorders, 2022-2032, $ bn 101
Figure 56. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Orthopedics, 2022-2032, $ bn 102
Figure 57. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Other Applications, 2022-2032, $ bn 103
Figure 58. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Drug Type, 2022-2032, % of Revenue 104
Figure 59. Contribution to North America 2023-2032 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%) 105
Figure 60. North America Active Pharmaceutical Ingredients (API) Market by Drug Type: Branded Prescription Drugs, 2022-2032, $ bn 106
Figure 61. North America Active Pharmaceutical Ingredients (API) Market by Drug Type: Generic Prescription Drugs, 2022-2032, $ bn 107
Figure 62. North America Active Pharmaceutical Ingredients (API) Market by Drug Type: OTC Drugs, 2022-2032, $ bn 108
Figure 63. Breakdown of North America Active Pharmaceutical Ingredients (API) Market by Country, 2022 and 2032, % of Revenue 110
Figure 64. Contribution to North America 2023-2032 Cumulative Revenue by Country, Value ($ bn) and Share (%) 111
Figure 65. U.S. Active Pharmaceutical Ingredients (API) Market, 2022-2032, $ bn 113
Figure 66. Manufacturing Sites of APIs for U.S. Market by Country or Region, 118
Figure 67. Number and Percentage of API Facilities for the 370 U.S. Marketed Drugs on the 2019 WHO Essential Medicines List 118
Figure 68. Number and Percentage of API Facilities for the 370 U.S. Marketed Drugs on the 2019 WHO Essential Medicines List 119
Figure 69. Canada Active Pharmaceutical Ingredients (API) Market, 2022-2032, $ bn 122
Figure 70. Active Pharmaceutical Ingredients (API) Market in Mexico, 2022-2032, $ bn 124
Figure 71. Growth Stage of North America Active Pharmaceutical Ingredients (API) Industry over the Forecast Period 126
Figure 72. AstraZeneca: Breakdown of Revenue by Therapy Area, 2022 133
Figure 73. AstraZeneca: Breakdown of Revenue by Region, 2022 133
Figure 74. Boehringer Ingelheim: Revenue by Business Segment, 2019-2022 148
Figure 75. Boehringer Ingelheim: R&D Investement, 2019-2022 149

List of Tables


List of Tables:

Table 1. Snapshot of North America Active Pharmaceutical Ingredients (API) Market in Balanced Perspective, 2022-2032 19
Table 2. World Economic Outlook, 2021-2031 23
Table 3. World Economic Outlook, 2021-2023 24
Table 4. Scenarios for Economic Impact of Ukraine Crisis 33
Table 5. World Health Spending by Region, $ bn, 2013-2020 42
Table 6. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn 43
Table 7. Main Product Trends and Market Opportunities in North America Active Pharmaceutical Ingredients (API) Market 47
Table 8. North America Active Pharmaceutical Ingredients (API) Market by Molecule, 2022-2032, $ bn 55
Table 9. North America Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn 59
Table 10. North America Active Pharmaceutical Ingredients (API) Market: Synthetic API by Drug Type, 2022-2032, $ bn 61
Table 11. North America Active Pharmaceutical Ingredients (API) Market: Biotech API by Drug Type, 2022-2032, $ bn 65
Table 12. North America Active Pharmaceutical Ingredients (API) Market: Biotech API by Category, 2022-2032, $ bn 70
Table 13. North America Active Pharmaceutical Ingredients (API) Market: Biotech API by Expression Technology, 2022-2032, $ bn 73
Table 14. North America Active Pharmaceutical Ingredients (API) Market: HPAPI by Drug Type, 2022-2032, $ bn 79
Table 15. North America Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn 82
Table 16. North America Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing by Drug Type, 2022-2032, $ bn 84
Table 17. North America Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Type, 2022-2032, $ bn 88
Table 18. North America Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Synthesis, 2022-2032, $ bn 91
Table 19. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn 94
Table 20. North America Active Pharmaceutical Ingredients (API) Market by Drug Type, 2022-2032, $ bn 104
Table 21. North America Active Pharmaceutical Ingredients (API) Market by Country, 2022-2032, $ bn 110
Table 22. U.S. Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn 114
Table 23. U.S. Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn 114
Table 24. U.S. Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn 114
Table 25. Top 15 Countries Supplying API for Medicines Consumed in the US, 2019, % based on Dollar Value 116
Table 26. Canada Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn 123
Table 27. Canada Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn 123
Table 28. Canada Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn 123
Table 29. Mexico Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn 125
Table 30. Mexico Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn 125
Table 31. Mexico Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn 125
Table 32. AbbVie Inc.: Company Snapshot 130
Table 33. AbbVie Inc.: Business Segmentation 131
Table 34. AbbVie Inc.: Product Portfolio 131
Table 35. Astrazeneca: Company Snapshot 132
Table 36. Aurobindo Pharma Ltd.: Company Snapshot 137
Table 37. Aurobindo Pharma Ltd.: Product Portfolio 138
Table 38. BASF: Company Snapshot 140
Table 39. BASF: Business Segmentation 141
Table 40. Bayer AG: Company Snapshot 143
Table 41. Bayer AG: Business Segmentation 144
Table 42. Bayer AG: Product Portfolio 144
Table 43. Boehringer Ingelheim: Company Snapshot 147
Table 44. Boehringer Ingelheim: Product Portfolio 148
Table 45. Catalent Inc.: Company Snapshot 152
Table 46. Catalent Inc.: Business Segmentation 153
Table 47. Catalent Inc.: Product Portfolio 153
Table 48. Dr. Reddy’s Laboratories: Company Snapshot 155
Table 49. Dr. Reddy’s Laboratories: Business Segmentation 155
Table 50. F. Hoffmann-La Roche: Company Snapshot 157
Table 51. F. Hoffmann-La Roche: Clinical Trial Service 157
Table 52. F. Hoffmann-La Roche: Business Segmentation 158
Table 53. F. Hoffmann-La Roche: Revenue by Region 158
Table 54. GlaxoSmithKline: Company Snapshot 160
Table 55. GlaxoSmithKline: Business Segmentation 161
Table 56. GlaxoSmithKline: Product Portfolio 162
Table 57. Lonza Group: Company Snapshot 165
Table 58. Lonza Group: Business Segmentation 166
Table 59. Lonza Group: Product Portfolio 166
Table 60. Lupin Limited: Company Snapshot 169
Table 61. Lupin Limited: Business Segmentation 170
Table 62. Merck & Co., Inc.: Company Snapshot 172
Table 63. Merck & Co., Inc.: Business Segmentation 173
Table 64. Mylan NV: Company Snapshot 175
Table 65. Mylan NV: Breakdown of Revenue by Region, 2022 176
Table 66. Mylan NV: Breakdown of Revenue by Product Category, 2022 176
Table 67. Novartis International AG: Company Snapshot 178
Table 68. Novartis International AG: Business Segmentation 179
Table 69. Pfizer Inc.: Company Snapshot 181
Table 70. Pfizer Inc.: Business Segmentation 182
Table 71. Pfizer Inc.: Breakdown of Revenue by Product Category 182
Table 72. Pfizer Inc.: Breakdown of Revenue by Region 183
Table 73. Pfizer Inc.: Product Portfolio 183
Table 74. Sanofi: Company Snapshot 186
Table 75. Sanofi: Business Segmentation 187
Table 76. Sanofi: Breakdown of Revenue by Region 187
Table 77. Sun Pharmaceutical Industries Limited: Company Snapshot 189
Table 78. Teva Pharmaceutical Industries Ltd.: Company Snapshot 192
Table 79. Teva Pharmaceutical Industries Ltd.: Business Segmentation 193
Table 80. Thermo Fisher Scientific: Company Snapshot 194
Table 81. Thermo Fisher Scientific: Breakdown of Revenue by Business Segment, 2020, % 195
Table 82. Thermo Fisher Scientific: Breakdown of Revenue by Region, 2020, % 195